John S. Bomalaski
Impact in
- Biotechnology top 0.1%
- Cancer Research and Treatments
- Cancer Research top 1%
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Cancer Research and Treatments 72
- Genetics 43
- Virus-based gene therapy research 35
- Co-authors
- Mike A. Clark (23 shared papers)Frederick W. Holtsberg (11 shared papers)Mark Ensor (11 shared papers)M A Clark (12 shared papers)Stanley T. Crooke (4 shared papers)Steven A. Curley (5 shared papers)Robert B. Zurier (8 shared papers)Marion R. Steiner (3 shared papers)
- Journals
- Journal of Clinical Oncology (21 papers)The Journal of Immunology (6 papers)Blood (5 papers)Clinical Cancer Research (4 papers)Journal of Leukocyte Biology (4 papers)
- Partner nations
- United StatesUnited KingdomTaiwan
In The Last Decade
John S. Bomalaski
129 papers receiving 4.7k citations
Peers
Comparison fields: 5 of 127
- Biotechnology 1.8k
- Cancer Research 1.3k
- Biochemistry 434
- Genetics 1.1k
- Nephrology 267
Countries citing papers authored by John S. Bomalaski
This map shows the geographic impact of John S. Bomalaski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John S. Bomalaski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John S. Bomalaski more than expected).
Fields of papers citing papers by John S. Bomalaski
This network shows the impact of papers produced by John S. Bomalaski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John S. Bomalaski. The network helps show where John S. Bomalaski may publish in the future.
Co-authors
The 25 scholars most cited alongside John S. Bomalaski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 132 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. | 2002 | 263 |
| 2 | 2004 | 242 | |
| 3 | 2004 | 199 | |
| 4 | 2005 | 188 | |
| 5 | 1988 | 184 | |
| 6 | 2013 | 135 | |
| 7 | 1986 | 127 | |
| 8 | 2012 | 121 | |
| 9 | 2002 | 116 | |
| 10 | 2017 | 114 | |
| 11 | 1991 | 109 | |
| 12 | 1984 | 107 | |
| 13 | 2015 | 103 | |
| 14 | 2011 | 98 | |
| 15 | 2012 | 98 | |
| 16 | 1991 | 93 | |
| 17 | 2017 | 89 | |
| 18 | 2012 | 88 | |
| 19 | 1986 | 87 | |
| 20 | Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. | 2002 | 81 |
About John S. Bomalaski
John S. Bomalaski is a scholar working on Biotechnology, Genetics, Molecular Biology, Neurology and Oncology, having authored 132 papers that have together received 4.8k indexed citations. Recurring topics across this work include Cancer Research and Treatments (72 papers), Virus-based gene therapy research (35 papers), Neuroblastoma Research and Treatments (22 papers), Cancer, Hypoxia, and Metabolism (19 papers), Nanoplatforms for cancer theranostics (9 papers), Biochemical and Molecular Research (7 papers), Peroxisome Proliferator-Activated Receptors (7 papers) and Inflammatory mediators and NSAID effects (7 papers). The work is most often cited by research in Biotechnology (1.8k citations), Cancer Research (1.3k citations), Biochemistry (434 citations), Genetics (1.1k citations) and Nephrology (267 citations). John S. Bomalaski has collaborated with scholars based in United States, United Kingdom and Taiwan. Frequent co-authors include Mike A. Clark, Frederick W. Holtsberg, Mark Ensor, M A Clark, Stanley T. Crooke, Steven A. Curley, Robert B. Zurier, Marion R. Steiner, Peter W. Szlosarek and Achim A. Jungbluth. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Immunology, Blood, Clinical Cancer Research and Journal of Leukocyte Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.